RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts
- Study successfully meets its primary effectiveness objectives and its secondary safety and tolerability objectives.- Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcy...
Page (1) of 1 - 05/18/18||
(May 18, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved